Depending on the medication and the patient population, research and approvals have supported benefits in areas like: Cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity (for specific products) Kidney protection in people with type 2 diabetes and chronic kidney disease (semaglutide showed benefit in a large kidney outcomes trial) Obstructive sleep apnea in adults with obesity (tirzepatide has an FDA-approved indication for moderate to severe OSA in this population) Fatty liver disease and MASH (semaglutide has shown promising results in phase 3 research) Addiction to opioids and alcohol This is why these medications are now part of bigger medical conversations: heart, kidney, liver, sleep health and substance abuse
An accidental career in gut biology and the tremendous excitement of GLP-1 medicines in the clinic-how did that happen
Turns Fat into Energy L-Carnitine helps transport fatty acids into cells where they are converted into energy
Another class of medications initially developed for the treatment of high blood glucose in patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitors (SGLT2i), has also been demonstrated to reduce cardiovascular risk, with corresponding FDA product label changes and professional society recommendations endorsing their use
& Ou, J
However, its benefits extend beyond this specialization
